Cancer Risk Reduction Through Combined Treatment for Tobacco and Alcohol Use
OBJECTIVES:
- To evaluate the effects of a motivational and problem-solving smoking cessation (MAPS)
and a motivational and problem solving approach on at-risk alcohol use and smoking
cessation (MAPS+) among Puerto Rican at-risk drinkers/smokers who call the Puerto Rico
Quitline (PRQ).
- To assess effects of MAPS and MAPS+ on treatment mechanisms and the role of those
mechanisms in mediating these effects on at-risk drinking and smoking cessation.
- To evaluate the cost-effectiveness of MAPS and MAPS+ in the reduction of at-risk
drinking and smoking cessation.
OUTLINE: Minimization randomization is applied using the following variables: age, gender,
cigarettes/day, number of drinks/day, and depression (score on the Center of Epidemiologic
Studies Depression Scale). Patients are randomized to 1 of 2 intervention arms.
- Arm I (MAPS): Patients receive culturally sensitive self-help materials tailored for
alcohol and tobacco users and 7 telephone counseling calls. The MAPS approach includes
motivational interviewing and cognitive behavioral/problem-solving that focus on
smoking cessation.
- Arm II (MAPS+): Patients receive culturally sensitive self-help materials tailored for
alcohol and tobacco users and 7 telephone counseling calls. The MAPS+ approach includes
motivational interviewing and cognitive behavioral/problems solving that focus on
smoking cessation and the reduction of at-risk alcohol use.
In both arms, patients receive counseling calls over 15-30 minutes the week before quit date
(QD), on QD, 3-5 days after QD, 7-10 days after QD, 15-30 days after QD, 45-60 days after
QD, and on day 90 after QD. Patients complete questionnaires for alcohol- and
smoking-related measures, self efficacy, stress/negative affects/depression, social support,
and physical activity at baseline and weeks 12, 26 and 52 after QD.
Observational
Observational Model: Case Control, Time Perspective: Prospective
Participant At-risk drinking status
52 weeks
No
David Wetter, PhD, MS, BA
Study Chair
M.D. Anderson Cancer Center
United States: Institutional Review Board
CDR0000626365
NCT00799669
February 2009
Name | Location |
---|